^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XP-102

    i
    Other names: XP-102, BI 882370, BI882370, XP102, BI-882370, XP 102
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, Xynomic
    Drug class:
    pan-RAF inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102
    over2years
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc. | Initiation date: Jun 2022 --> Dec 2022
    Trial initiation date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102
    over2years
    ENHANCE: XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (clinicaltrials.gov)
    P1/2, N=221, Not yet recruiting, Xynomic Pharmaceuticals, Inc.
    New P1/2 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • XP-102